Bob Costas Returns as Emcee for New York Fundraiser on Monday, September 26 to Benefit The Buoniconti Fund to Cure Paralysis
The Johnson & Johnson Campaign for Nursing's Future sponsors national contest, honoring nurses' dedication to the profession.
Peer-reviewed study involving more than 3 million pharmacy patients shows calendar blister packaging improves adherence to self-administered medications for long-term use.
Local and national partners unite to improve maternal and infant health one text at a time.
Join the Johnson & Johnson Campaign for Nursing’s Future during National Nurses Week and take this opportunity to thank a nurse.
National survey finds parents and coaches need more youth sports safety information.
National findings reveal greater awareness, earlier diagnosis, and support help reduce daily life challenges
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting.
Commitment from Johnson & Johnson Enables Growth of Nation’s Largest Mobile Health Initiative.
Data from the first phase III clinical trial of NovoCure’s NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, noninvasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
“Health” joins “Green.” From inspired cause to pervasive business imperative, leadership in health and health- issues has emerged as a smart new business strategy that can drive purchasing, loyalty decisions and trust, according to a new 11-country survey of 15,000+ people being released next week at the 7th Annual World Heath Care Congress in Washington, D.C.
New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke. The studies were presented at the 1st International Congress on Abdominal Obesity in Hong Kong earlier today.
Church & Dwight Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the FIRST RESPONSE® Early Result Pregnancy Test which can determine pregnancy up to six days before the day of a woman’s missed period.
Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: “Bridging the Gap between Cardiology and Diabetology.” The congress, sponsored by the International Chair on Cardiometabolic Risk (ICCR) (www.cardiometabolic-risk.org), is the first-ever specialized forum for sharing new insights and evidence about abdominal obesity and its clinical and public health implications.
Are Americans in denial about their eating habits? Today, two out of three Americans are overweight or obese, and by 2030 that figure will balloon to nearly nine out of 10. Yet in a new national survey, three-quarters of respondents (74%) said they have a healthy personal relationship with food—revealing a clear disconnect between how we think and how we act when it comes to eating. GlaxoSmithKline Consumer Healthcare, the maker of alli®, sponsored the survey to better understand America’s unhealthy relationship with food and develop solutions to help people change the way they eat.
As the healthcare reform debate continues, legislators and businesspeople alike might be surprised to learn that Americans are looking not only to government but also to business to improve our nation’s health, even beyond employee wellness efforts. People are more likely to purchase from, recommend, and invest in companies that act on health issues—creating a compelling case for businesses to step up their efforts.
A new article published in the peer-reviewed journal Women’s Health emphasizes the importance of early pregnancy detection. Using research conducted on behalf of Church & Dwight Co. Inc., the makers of First Response, the article reviews data that shows not all at-home pregnancy tests are created equal –First Response® brand pregnancy tests are more sensitive and able to detect key variants of the pregnancy hormone better than other at home pregnancy tests.
Bausch & Lomb announces the appointment of Mohinder Merchea, O.D., Ph.D., MBA, FAAO, FBCLA, to director of Medical Affairs, North America, Vision Care. Dr. Merchea will serve as the department’s liaison to academic institutions and professional organizations, communicating with key leaders in the field and representing the views of eye care professionals to the company.
Tibotec Therapeutics is launching a new initiative to raise awareness of issues affecting women and people of color living with HIV/AIDS through a comprehensive campaign including local educational events, media outreach and a new Web site, www.TheGraceStudy.com.
Bausch & Lomb today announced that the company’s Lo-Torque® lens design demonstrates significantly better rotational recovery, which can lead to more consistent vision, compared with Acuvue’s accelerated stabilization design.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right